Multifaceted Role of the Transforming Growth Factor β on Effector T Cells and the Implication for CAR-T Cell Therapy
Open Access
- 25 June 2021
- Vol. 1 (3), 160-173
- https://doi.org/10.3390/immuno1030010
Abstract
Evading the immune system is one of the hallmarks of cancer. Tumors escape anti-tumor immunity through cell-intrinsic means and the assembly of an immunosuppressive tumor microenvironment. By significantly boosting the host immune system, cancer immunotherapies targeting immune checkpoint receptors (CTLA-4 and PD-1) improved survival in patients even with cancers previously considered rapidly fatal. Nevertheless, an important group of patients is refractory or relapse rapidly. The factors involved in the heterogeneous responses observed are still poorly understood. Other immunotherapeutic approaches are being developed that may widen the options, including adoptive cell therapy using CAR-T cells alone or in combination. Despite impressive results in B cell malignancies, many caveats and unanswered questions remain in other cancers, thus limiting the potential of this approach to treat aggressive diseases. In particular, a complex TME could impair the survival, proliferation, and effector functions of CAR-T cells. Recent reports highlight the potential of targeting TGF-β signaling to improve CAR-T cell therapy. TGF-β is a well-known regulatory cytokine with pleiotropic effects in the TME, including immunosuppression. This review summarizes recent work investigating the potential effects of TGF-β within the TME, with a focus on CAR-T behavior and efficacy. We also discuss several key questions to be addressed to accelerate clinical translation of this approach.Keywords
Funding Information
- Association pour la Recherche sur les Tumeurs de la Prostate (not applicable)
This publication has 86 references indexed in Scilit:
- The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive OverviewCancers, 2020
- Engineering CAR-T Cells for Next-Generation Cancer TherapyCancer Cell, 2020
- Engineering strategies to overcome the current roadblocks in CAR T cell therapyNature Reviews Clinical Oncology, 2020
- Top 10 Challenges in Cancer ImmunotherapyImmunity, 2020
- Tumour-intrinsic resistance to immune checkpoint blockadeNature Reviews Immunology, 2019
- Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significanceJournal for ImmunoTherapy of Cancer, 2018
- The hallmarks of successful anticancer immunotherapyScience Translational Medicine, 2018
- Understanding the tumor immune microenvironment (TIME) for effective therapyNature Medicine, 2018
- Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyJournal of Clinical Oncology, 2017
- Hallmarks of Cancer: The Next GenerationCell, 2011